Case report: Dupilumab leads to an increased chance of head and neck Staphylococcus aureus infection in atopic dermatitis patients
Dupilumab was the first biological medication licensed to treat atopic dermatitis (AD), and it has shown remarkable effectiveness and safety in the treatment of moderate-to-severe atopic dermatitis. There are limited drug-related adverse events associated with dupilumab in atopic dermatitis (AD) tre...
Main Authors: | Min Chen, Kai Gao, Kamran Ali, Jinpeng Shan, YunMi Qiu, Tianci Xie, Yiling Yu, Liming Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-03-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1027589/full |
Similar Items
-
Dupilumab-induced Acute Generalized Exanthematous Pustulosis in a 17-year-old Female Chinese Patient with Atopic Dermatitis
by: LiMing Wu, et al.
Published: (2022-06-01) -
Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis?
by: Federica Gelato, et al.
Published: (2023-03-01) -
Is Dupilumab a chance for patients with moderate to severe atopic dermatitis? Literature review
by: Paweł Iwańczuk
Published: (2024-02-01) -
A case of leukocytoclastic vasculitis in a patient on dupilumab
by: Michelle S. Bach, BS, et al.
Published: (2023-12-01) -
Changes in Skin and Nasal Microbiome and Staphylococcal Species Following Treatment of Atopic Dermatitis with Dupilumab
by: Caroline Meyer Olesen, et al.
Published: (2021-07-01)